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Background: A key therapeutic approach to asthma, which is characterized by chronic airway inﬂam-
mation, is inhaled corticosteroid (ICS). This study evaluated the association of symptom control with
changes in lung function, bronchial hyperresponsiveness (BHR), and exhaled nitric oxide (eNO) after ICS
treatment in asthmatic children.
Methods: A total of 33 children aged between 5 and 12 years with mild to moderate persistent asthma
were treated with 160 mg ciclesonide per day for 3 months. At days 0 and 90, the following parameters
were assessed: asthma symptom scores; lung function, including forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), and forced expiratory ﬂow at 25e75% of forced vital capacity (FEF25
e75%); BHR to methacholine and adenosine 5-monophosphate (AMP); and eNO.
Results: Asthma symptom scores, lung function parameters, BHR to methacholine and AMP, and eNO
levels at day 90 were signiﬁcantly improved versus day 0 (all p < 0.001). Symptom scores at day 90 were
not correlated with changes in lung function and BHR to methacholine during the follow-up period,
whereas those at day 90 were more closely correlated with changes in BHR to AMP (r ¼ 0.511, p ¼ 0.003)
than with eNO (r ¼ 0.373, p ¼ 0.035). Additionally, changes in PC20 AMP were correlated with changes
in PC20 methacholine (r ¼ 0.451, p ¼ 0.011) and eNO (r ¼ 0.474, p ¼ 0.006).
Conclusions: Changes in the BHR to AMP, and to a lesser extent eNO, correlate with asthma symptom
control after ICS treatment. BHR to AMP may better reﬂect the relationship between improved airway
inﬂammation due to ICS treatment and asthma symptoms.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma involves chronic airway inﬂammation characterized by
bronchial hyperresponsiveness (BHR) and reversible airway
obstruction. Therefore, treatment with anti-inﬂammatory agents,
such as inhaled corticosteroid (ICS), represents the main effective
therapy for asthma management. Current guidelines on asthmarics, Asan Medical Center,
-ro 43-gil, Songpa-gu, Seoul
ety of Allergology.
rgology. Production and hosting by Elsemanagement adhere to the concept that treatment should aim to
reduce or prevent airway inﬂammation with ICS and that adjust-
ments of the ICS dose for treatment are guided solely by symptoms
and lung function.1 However, the current stepwise strategy for
symptom and lung function optimization does not lead to proper
control of asthma in all patients.2 Moreover, in patients with
asthma that is considered to be under control, airway inﬂammation
can persist3e5 and such abnormalities can cause airway remodeling
and reductions in lung function during the long-term follow-up
period.6 Therefore, objective evaluation of airway inﬂammation
and its consequences, as well as the evaluation of symptoms, is
needed to achieve proper asthma control.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
G.-M. Park et al. / Allergology International 65 (2016) 439e443440Many studies have tried to use BHR or inﬂammation markers as
objective markers of the effects of ICS.2,7,8 It is generally accepted
that airway inﬂammation contributes to the presence and severity
of BHR, but reports of a direct association between airway inﬂam-
mation and BHR have varied according to the method used to
measure BHR.5,9,10 Several studies have shown that BHR to aden-
osine 5-monophosphate (AMP), an indirect stimulus, is an earlier
and more sensitive indicator of the effects of ICS than BHR to
methacholine, a direct stimulus.11e14 In addition, exhaled nitric
oxide (eNO) reﬂects airway inﬂammation, and changes in eNO after
ICS are rapid and reproducible,15e17 although eNO levels seem to be
affected by several factors.18e22
However, there is little information to simultaneously relate
these objective makers, including BHR to direct or indirect stimuli
and airway inﬂammation markers, to asthma symptom control
during ICS treatment in children with asthma. Accordingly, the
present study aimed to evaluate the association of symptom scores
with changes in lung function, BHR to methacholine or AMP, and
eNO after ICS treatment in children with asthma.
Methods
Subjects and study design
A series of 33 childrenwith mild to moderate persistent asthma,
aged 5e12 years, was recruited from August to October 2012 from
the Childhood Asthma Atopy Center at Asan Medical Center Chil-
dren's Hospital. All subjects met the following criteria: airway
reversibility to b2-agonist 12% of the predicted forced expiratory
volume in one second (FEV1) and/or symptom relief using a bron-
chodilator, a history of recurrent wheezing and/or dyspnea within
the previous 12 months, and no severe comorbidities, including
bronchiolitis obliterans, malignancy, and congenital heart disease
affecting lung function. Before treatment with ICS, all patients were
(by design) responsive to methacholine (provocative concentration
causing a 20% fall in FEV1, PC20  25 mg/mL) and AMP
(PC20  400 mg/mL). Deﬁnition of disease severity was based on
the criteria set in the National Asthma Education and Prevention
Program (NAEPP) guidelines.1
All subjects were treated with 160-mg ciclesonide per day
(Alvesco®, Takeda Pharmaceuticals, Dubendorf, Switzerland) for 3
months, which was administrated with or without a spacer (Vor-
tex®, PARI GmbH, Starnberg, Germany) that was ﬁtted to the
mouthpiece, depending on the patient age and inhaler perfor-
mance. At both days 0 and 90, the following parameters were
assessed: asthma symptom scores; lung function, including forced
expiratory volume in one second (FEV1), forced vital capacity (FVC),
and forced expiratory ﬂow at 25%e75% of forced vital capacity
(FEF25e75%); BHR to methacholine and AMP; and levels of eNO.
The study protocol was approved by the Institutional Review
Board of the Asan Medical Center and all participants gave written
informed consent after receiving a detailed explanation of the
study.
Measurements of lung function and BHR
Basal lung function, including measurements of the FEV1, FVC,
and FEF25e75%, and two bronchial provocation test with meth-
acholine and AMP were performed in all subjects on the same day.
The value of the FEV1 and FEF25e75% were expressed as a percentage
of the predicted value for the global lung function 2012 equations.23
After methacholine challenge, an AMP challenge was carried out
after recovery of the FEV1 to within 5% of the baseline FEV1 of a
methacholine challenge. Antihistamines, bronchodilators, and
other medications were not taken for 48 h before testing on days0 and 90. ICS administrationwas stopped for 14 days before testing
at day 0, but was continued at day 90.
Methacholine and AMP were prepared in 0.9% saline solution at
concentrations of 0.625e25 mg/mL for methacholine (0.625, 1.25,
2.5, 5, 10, and 25 mg/mL) and 3.125e400 mg/mL for AMP (3.125,
6.25, 12.5, 50, 100, 200, and 400 mg/mL). The FVC and FEV1 values
were measured at 1 and 3 min in the methacholine and AMP tests
after each administration. The challenge was terminated if FEV1
dropped by >20% from post-saline value or if maximal concentra-
tion of methacholine or AMPwas administered. PC20was calculated
by linear interpolation of the log-dose-response curves.Measurements of eNO levels
The eNO fraction was measured using a Niox Mino device
(Aerocrine, Solna, Sweden) using a previously described method
before bronchial provocation test.24Asthma control assessments
We modiﬁed a previous questionnaire for assessing asthma
symptom scores.25,26 Patients were asked to recall their symptoms
during the previous month at each visit, and symptom scores
included wheezing, use of a short-acting bronchodilator, shortness
of breath, nocturnal symptoms, activity limitation, and overall
asthma control. All six questions were scored on a 5-point scale,
and a high score indicated good asthma control.Measurements of atopy
A skin prick test (SPT) was performedwith 31 common allergens
using standard methods27: Dermatophagoides pteronyssinus,
D. farinae, Alternaria, Aspergillus, Cladosporium, Penicillium, grasses,
trees, weeds, ragweed, mugwort, oak, beech, nettle, willow, elm,
pine, hop, elder, hazel, oats, lambs quarter, ash, alder, birch,
timothy, rye grass, dog, cat, and cockroach. SPT was included a
positive control (histamine) and a negative control (isotonic saline).
A positive on SPT was deﬁned as a meanwheal diameter of 3 mm
and greater than that of the histamine. Atopy was deﬁned as pos-
itive SPT result to at least one allergen.Total serum IgE and blood eosinophils
Total serum IgE levels were measured with immunoCAP system
(Phadia AB, Uppsala, Sweden). Blood eosinophil counts were
measured using an automated blood analyzer.Statistical analyses
Data are presented as means ± SD or as geometric means with a
range of 1 SD. Levels of total IgE, blood eosinophil counts, PC20
methacholine, PC20 AMP, and eNO were log-transformed prior to
analysis to normalize the distribution or these values. Variables
were then compared using the paired t-test, and frequencies were
compared using the c2 test. Correlations between variables were
analyzed using Pearson's correlation test. Changes in PC20 meth-
acholine and PC20 AMP after 3 months of ICS treatment versus
pretreatment values were expressed as dose shifts (in doubling
doses) using the following formula: Dlog10PC20 ¼ [log10(PC20 after
the treatment)  log10(PC20 before the treatment)]/log102.28,29 A p-
value of 0.05 or less was considered to be signiﬁcant. The SPSS
version 19 software package was used for these analyses (SPSS Inc.,
Chicago, IL, USA).
Table 2
Changes in symptom scores, lung function, bronchial hyperresponsiveness, and
exhaled NO during the follow-up period.
Day 0 Day 90 Change from
baseline
Symptom
score
24.42 ± 4.38 27.79 ± 2.67* 3.36 ± 4.39
FEV1% pred 99.06 ± 10.92 110.56 ± 12.77* 12.21 ± 12.47
FEF25e75%
pred
89.45 ± 26.57 105.07 ± 31.07* 20.88 ± 32.00
PC20
methacholine,
mg/mLy
2.82 (1.20e6.61) 12.59 (3.31e47.86)* 2.16 ± 1.54
PC20 AMP,
mg/mLy
63.10 (17.78e223.87) 478.63
(141.25e1621.81)*
2.91 ± 1.59
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Characteristics of the study subjects
The mean age of the 33 subjects was 6.95 ± 1.83 years, and the
proportions of male patients and atopy were 72.7% and 81.8%,
respectively. The FEV1, FEF25e75%, and FEV1/FVC values were
99.06± 10.92% pred (predicted), 89.45± 26.57% pred, and
0.86±0.09, respectively. The geometricmeans (rangeof 1SD)of PC20
methacholine, PC20 AMP, eNO, blood eosinophils, and total IgEwere
2.82 (1.20e6.61), 63.10 (17.78e223.87), 19.50 (10.96e34.67), 5.25
(2.82e9.77), and 257.04 (83.18e794.33), respectively. The charac-
teristics of the children analyzed in this study are listed in Table 1.eNO, ppbz 19.50 (10.96e34.67) 10.23 (4.90e21.38)* 0.28 ± 0.33
Data are expressed as means ± SD or geometric means (range of 1 SD).
y Changes in PC20 methacholine and PC20 AMP versus pretreatment values were
expressed as doubling doses.
z Changes in log eNO versus pretreatment values.
* p < 0.001.Changes in lung function, BHR, eNO, and symptom scores after 3
months of ICS treatment
We examined the symptom scores, lung function, BHR, and eNO
at days 0 and 90 (Table 2). The asthma symptom scores, parameters
for lung function, BHR to methacholine and AMP, and levels of eNO
at day 90 were all signiﬁcantly improved compared with those at
day 0 (all p < 0.001). The changes in asthma symptom scores, FEV1%
pred, and FEF25e75%% pred after 3 months of ICS treatment were
3.36 ± 4.39, 12.21 ± 12.47, and 20.88 ± 32.00, respectively. The
changes in PC20 methacholine and PC20 AMP, expressed as doubling
doses, were 2.16 ± 1.54 and 2.91 ± 1.59 after 3 months of ICS
treatment, respectively. The change in the log eNO values
was 0.28 ± 0.33 after 3 months of ICS treatment.
The rates of BHR to methacholine (<8 mg/mL) were 87.9% at day
0 and 45.5% at day 90. The rates of BHR to AMP (<200 mg/mL) were
84.8% at day 0 and 15.2% at day 90. The rates of positive responses in
eNO (>20 ppb in subjects younger than 12 years and >25 ppb in
subjects older than 12 years) were 54.5% at day 0 and 21.2% at day
90. The rates of BHR to methacholine or AMP and positive re-
sponses in eNO were signiﬁcantly reduced after 3 months of ICS
treatment (all p < 0.05).Associations between symptom scores at day 90 and changes in lung
function, BHR, and levels of eNO
At baseline, symptom scores were not correlated with lung
function, BHR to methacholine or AMP, or eNO levels. However, theTable 1
Baseline characteristics of the study subjects.
Variables N ¼ 33
Age, years 6.95 ± 1.83
Males/females 24/9
Height, cm 120.48 ± 11.59
Weight, kg 24.19 ± 9.55
Atopy, n (%) 27 (81.8%)
Allergic rhinitis 21 (63.6%)
Symptom score 24.42 ± 4.38
FEV1% pred 99.06 ± 10.92
FEV1/FVC 0.86 ± 0.09
FEF25e75%% pred 89.45 ± 26.57
PC20 methacholine, mg/mL 2.82 (1.20e6.61)
PC20 AMP, mg/mL 63.10 (17.78e223.87)
Exhaled nitric oxide, ppb 19.50 (10.96e34.67)
Blood eosinophils/mm3 (%) 5.25 (2.82e9.77)
Total IgE, KU/L 257.04 (83.18e794.33)
Asthma severity, n (%)
Mild, intermittent 0
Mild, persistent 30 (90.9%)
Moderate, persistent 3 (9.1%)
Severe, persistent 0
Data are expressed as means ± SD or geometric means (range of 1 SD).levels of FEV1% pred were correlated with the levels of PC20
methacholine, PC20 AMP, and eNO (r ¼ 0.476, p < 0.01; r ¼ 0.416,
p < 0.05; and r ¼ 0.384, p < 0.05, respectively) at day 0, and the
levels of PC20 AMP were correlated with the levels of eNO at day
0 (r¼0.467, p< 0.01; Table 3). Symptom scores at day 90were not
correlatedwith changes in lung function or PC20methacholine after
3 months of treatment (Table 4). However, the symptom scores at
day 90 were correlated with the changes in PC20 AMP (r ¼ 0.511,
p < 0.01) and log eNO (r ¼ 0.373, p < 0.05) after 3 months of
treatment. Additionally, the changes in PC20 AMP were correlated
with the changes in PC20 methacholine (r ¼ 0.451, p < 0.05) and log
eNO (r ¼ 0.474, p < 0.01) after 3 months of treatment.
Discussion
In our present study, asthma symptom scores and the
parameters for lung function, BHR, and levels of eNO improved
signiﬁcantly after 3 months of ICS treatment. Although changes in
lung function and BHR to methacholine during ICS treatment were
not correlatedwith asthma symptomscores, changes in BHR toAMP
and levels of eNO were correlated with asthma symptom scores.
Furthermore, changes in the BHR to AMP showed a more robust
correlationwith asthma symptom scores than changes in the levels
of eNO.
In our current analyses, asthma control based on symptom
scores was found to be associated with changes in BHR to AMP after
ICS treatment but was not correlated with changes in BHR to
methacholine. Methacholine, a direct stimulus, acts directly on the
airway smooth muscle causing the airway obstruction in patients
with asthma.30,31 Measurements of BHR to methacholine are more
closely associated with FEV1, which represents baseline airway
caliber, than BHR to AMP, an indirect stimulus, which represents a
better indicator of airway inﬂammation in asthmaticTable 3
Relationships between the symptom score, lung function, BHR, and eNO at day 0.
FEV1% pred FEF25e75% pred log PC20
methacholine
log PC20
AMP
log eNO
Symptom score r 0.158 0.107 0.152 0.001 0.076
FEV1% pred r e 0.538* 0.476* 0.416** 0.384**
FEF25e75% pred r e e 0.491* 0.360** 0.288
log PC20
methacholine
r e e e 0.191 0.144
log PC20 AMP r e e e e 0.467*
* p < 0.01.
** p < 0.05.
Table 4
Relationships between symptom scores and changes in lung function, BHR, and eNO
at day 90.
DFEV1%
pred
DFEF25e75%%
pred
DPC20
methacholiney
DPC20
AMPy
DeNOz
Symptom score r 0.088 0.110 0.278 0.511* 0.373**
DFEV1% pred r e 0.717* 0.311 0.319 0.159
DFEF25e75%% pred r e e 0.289 0.272 0.089
DPC20
methacholine
r e e e 0.451** 0.099
DPC20 AMP r e e e e 0.474*
y Changes in PC20 methacholine and PC20 AMP versus pretreatment values were
expressed as doubling doses.
z Changes in log eNO versus pretreatment values.
* p < 0.01.
** p < 0.05.
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smooth muscle, AMP acts on mast cells by binding to the adenosine
A2B receptor and increasing the release of inﬂammatory mediators
such as histamine, prostaglandins, tryptase, and leukotrienes from
mast cells.34,35 Additionally, other studies demonstrated that PC20
AMP is a more sensitive method for evaluating airway inﬂamma-
tion after ICS treatment than PC20 methacholine.12,36 These previ-
ous results support our ﬁnding that asthma symptom scores are
associated with changes in BHR to AMP rather than changes in BHR
to methacholine after ICS treatment.
Levels of eNO are related to eosinophilic airway inﬂammation,
measured in induced sputum and bronchoalveolar lavage ﬂuid,15,16
and the decrease in the levels of eNO during ICS treatment is rapid
and reproducible.17 In the present study, asthma symptom scores
were also associated with changes in the levels of eNO. Notably,
however, asthma symptom scores were found to be more closely
correlated with changes in BHR to AMP than changes in the levels
of eNO after ICS treatment. Moreover, changes in BHR to meth-
acholine were correlated with changes in BHR to AMP after ICS
treatment but not with changes in the levels of eNO. BHR to AMP
seems to have a component of BHR in response to ICS beyond
airway inﬂammation, represented by eNO levels. Only 60.7% of our
study subjects with BHR to AMP (<200 mg/mL) had higher levels of
eNO (>20 ppb in subjects younger than 12 years and >25 ppb in
subjects older than 12 years). The mechanism of mast cell mediator
release induced by challenge with mannitol, another indirect
stimulus, is similar to that of AMP challenge and causes broncho-
constriction.37 Almost 20% of asthmatic patients who had BHR to
mannitol had normal levels of eNO.38 In addition, BHR to mannitol
was not signiﬁcantly different between eosinophilic and non-
eosinophilic asthma phenotypes, whereas the levels eNO were
signiﬁcantly different between those phenotypes.39
The recent addition of eNO measurements to the present
guidelines for asthma management has resulted in the adminis-
tration of higher doses of ICS but has not achieved clinically sig-
niﬁcant improvements in asthma control.40 Moreover, eNO levels
are affected by several factors, including atopy, total IgE, other
allergic diseases, exposure to allergens, height, and food.18e22
Therefore, measurement of BHR to AMP might be a better tool to
predict the response to ICS than eNO levels, although conducting a
provocation test with AMP can be time-consuming.
In the current guidelines, the evaluation of asthma symptoms
that are subjectively reported by asthmatic children and their par-
ents is a core asthma outcome measurement. However, many chil-
drenwith asthmaare poor perceivers of airwayobstruction andvary
considerably in the degree of airway narrowing that they recog-
nize.41,42 Psychological factors are highly associated with asthma
symptomburden43 and increased requests for asthmamedication.44
Considering these demerits of asthma symptoms, treatment basedon symptoms alone may lead to either overtreatment or under-
treatment. Moreover, FEV1, an objective measurement included in
the current guidelines, doesnot correlatewellwith themagnitudeof
asthma symptoms in children.45 Therefore, objectivemeasurements
of the effect of ICS as well as the evaluation of asthma symptoms are
needed to achieve better asthma control.
Our current study is the ﬁrst to evaluate the associations of
asthma symptom scores with changes in lung function, BHR to
methacholine or AMP, and levels of eNO after ICS treatment in
children with asthma. However, our study period was too short to
make any strong inferences regarding the clinical application of
monitoring tools for asthma control. The childhood asthma control
test (C-ACT)26 and the asthma control questionnaire (ACQ)25 have
been extensively used to evaluate asthma symptoms in children
with asthma. These two instruments consist of similar questions
except for a question on the use of rescue medication, which is
included in the ACQ but not in the C-ACT. We believe that use of
rescue medication is an important factor for the assessment of
asthma control and have thus modiﬁed the C-ACT.We validated the
questionnaire used in this study, but the validation results have
unfortunately not been published yet (data not shown). All subjects
stopped ICS treatment for 14 days before testing at day 0. Two
weeks might be too short a period to neutralize the effects of ICS on
outcome values at day 0. However, all outcome values for the
comparison were assessed on the same day in each individual at
day 0 under the same conditions of a 2-week ICS withdrawal. There
is still a limitation that ICS might affect some outcome values,
particularly BHR to AMP and eNO, at day 0 and thus affect the
change in these values between day 0 and day 90 more than other
values, such as lung function.
In addition, we did not measure adherence to ICS during our
current study period. However, each value was assessed in each
individual under the same conditions of adherence. Most of our
subjects had mild persistent asthma, so our results might not be
representative of the entire asthmatic population. Although the
degree of change in each value was not high because the subjects
had mild persistent asthma, we observed signiﬁcant relationships
between changes in each value and asthma symptoms. Addition-
ally, AMP challenge was performed after methacholine challenge
on the same day. It is unlikely that methacholine challenge inﬂu-
enced the AMP challenge results because we performed the AMP
challengewhen the baseline FEV1 had recovered towithin 5% of the
baseline for methacholine challenge without any respiratory
symptoms that suggested airway obstruction. Therefore, baseline
airway calibers after methacholine challenge were not likely to
affect the PC20 for AMP challenge. Actually, in our present study, the
baseline FEV1 values for the two challenges were not signiﬁcantly
different (data not shown).
In conclusion, improvements in BHR to AMP and levels of eNO
after ICS treatment show a correlation with asthma symptom
scores, whereas improvements in lung function and BHR to
methacholine do not. Furthermore, BHR to AMP exhibits a more
robust correlationwith symptom scores than the levels of eNO. BHR
to AMP may better reﬂect the relationship between the improve-
ment in airway inﬂammation by treatment with ICS and asthma
symptoms. These ﬁndings suggest that PC20 AMP may be an
important parameter for the management of children with asthma
receiving ICS. Further long-term studies designed to assess whether
the use of PC20 AMP as a monitoring tool for asthma can improve
asthma control in the clinic are needed.
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